Efficacy and Safety of Lorlatinib in Korean Non-small-cell Lung Cancer Patients with ALK or ROS-1 Rearrangement Who Failed Previous Tyrosine Kinase Inhibitor
Efficacy and Safety of Lorlatinib in Korean Non-small-cell Lung Cancer Patients with ALK or ROS-1 Rearrangement Who Failed Previous Tyrosine Kinase Inhibitor
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More